Evotec’s Post

Join Us at Eurotox 2024! We are thrilled to invite you to two exciting events hosted by Evotec and Cyprotex at Eurotox 2024! Don't miss these opportunities to gain valuable insights and network with industry experts. Industry Hosted Session Topic: Navigating the Preclinical Development of Antibody Drug Conjugates (ADCs) Focus: Toxicology De-Risking Strategies for Enabling Personalized Medicine Date & Time: Monday, 9 September 2024, 12:00-13:00 Presenters: Dario Salerno, Senior Manager, Safety Assessment, and Giulia Iannoto, Immunotoxicologist, Safety Assessment Session Highlights: - Explore the complexities of ADCs, biopharmaceutical molecules designed to target cancer cells. - Understand the unique challenges in nonclinical safety assessment of ADCs. - Learn about the science-based approach to safety assessment and current regulatory guidelines. - Discover our recent case study and experiences with ADCs. Poster Presentation Title: Multiparametric In Vitro Assays Combined with High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Mechanistic Insight (#916) Date and time: Monday, 9 September 2024, 9:30am Presenter: Samantha Llewellyn, Associate Principal Scientist - Cyprotex Join us to delve into innovative methodologies for cardiotoxicity risk assessment and gain mechanistic insights through high-throughput RNA sequencing. Don't miss these sessions to stay at the forefront of toxicology and preclinical development. We look forward to seeing you there! #Eurotox2024 #ADCs #Toxicology #PreclinicalDevelopment #Cardiotoxicity #PersonalizedMedicine https://hubs.ly/Q02L3V0D0

#ADCs are in the limelight at the Evotec and Cyprotex-hosted session at the #EUROTOX Congress. Join Dario Salerno, and Giulia Iannoto, on Monday, 9 September 2024, 12:00-13:00 to learn how to navigate preclinical development for ADCs. #toxicology #safetyassessment #oncology #personalizedmedicine #drugdevelopment #researchneverstops #biopharmaceuticals #immunology #rnaseq #cardiotoxicity #antibody

So excited that we are hosting the #BAPTG spring meeting tomorrow! Looking forward to learning more about novel tools to accelerate drug discovery & development and regulatory guidance on safety assessment for cell therapy, ADCs & TCEs in oncology, autoimmunity, and other therapeutic areas. #celltherapy #toxicology #oncology #autoimmunity #immunology #AstraZeneca

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics. To find out more take a look at this frontrunners in bispecific antibodies article: https://lnkd.in/ehE36z29

Everything you missed in #Pharma & #Biotech 🦠🔬   ✅ Approvals Boston Scientific receives FDA approval for the AGENT Drug-Coated Balloon for coronary in-stent restenosis in coronary artery disease CHMP recommends Biogen’s Qalsody® (tofersen) for rare form of ALS (SOD1 gene mutation)   💸 Deals   AstraZeneca to acquire Gracell Biotechnologies for $1.2 Billion Amneal Pharmaceuticals, Inc. enters EU/UK/CH licensing agreement with Zambon Biotech for IPX203, oral carbidopa/levodopa extended-release capsules for Parkinson’s, currently under review with the FDA Idorsia Pharmaceuticals Ltd entered R&D agreement including two Ph3 assets (CV and autoimmune) with Viatris Abingworth offers Gilead Sciences up to $210 million to support select clinical studies of antibody-drug conjugate Trodelvy, with a focus on non-small cell lung cancer BlossomHill Therapeutics, Inc. raises $100 million in series B for oncology and autoimmune development Telix Pharmaceuticals Limited to aquire IsoTherapeutics Group LLC, a specialty radiopharmaceutical development and bioconjugation firm   Suven Pharmaceuticals and Cohance Lifesciences announce merger   Takeda partners with Biological E. Limited to boost dengue vaccine Qdenga® production     🎯Late-stage developments   MoonLake Immunotherapeutics (NASDAQ: MLTX) to advance IL-17 inhibitor into Ph3 following positive feedback from FDA and EMA   👀 To watch   Pfizer shares roadmap for cancer portfolio with vision to launch at least eight cancer blockbuster drugs by 2030 following Seagen acquisition, with focus on genitourinary (eg prostate and bladder), blood (eg multiple myeloma and lymphomas), breast, lung and head and neck   📈 Access   Delaware judge dismisses AstraZeneca's challenge to IRA drug price provisions. AZ’s diabetes, kidney and heart drug Farxiga is one of ten products facing Medicare price negotiations   ✳️ Other:   Biden administration invests $48M in AI/ML platform to identify rare disease drugs   👉 What’s your favorite industry news?   #pharma #biotech #PulseNews

Something to monitor in the field of Immunotherapy

Do you want to become incredibly well read on the latest drug therapies – in just a few minutes? 👇Then check out our brand new #DrugDevelopment blog – outlining the state-of-the art treatments that were approved by the FDA in 2023, a memorable year for novel therapies. https://okt.to/5ZwNIs 💡 The blog also previews some of the key drugs that are expected to be approved in 2024 – including an Alzheimer’s targeting monoclonal antibody and an MDMA treatment for PTSD. ✅ Getting up to speed on the latest therapeutic developments – from AKT inhibitors to Alzheimer’s disease, and oncology to orphan drugs – has never been so easy! ****** ***** ***** Did you know? LGC Standards’ Toronto Research Chemicals range supplies bioactive molecules for research into cancer, infectious diseases, neuroscience and more, while LGC Mikromol™ offers 5,000+ pharmaceutical reference standards. ***** ***** ***** #ScienceForASaferWorld

In this featured article on Labiotech.eu, our CEO 何正宏Jeng Her dives deep into the future of #bispecific antibodies, a promising therapeutic approach that is transforming treatment possibilities for #cancer and other diseases. From discussing the science behind bispecifics to exploring the key challenges in drug discovery, he emphasizes how innovation is reshaping the landscape of antibody-based treatments. Explore how our cutting-edge R&D is contributing to this revolution in immuno-oncology therapy! #IO

Merck will pay Curon Biopharmaceutical, a China-based biotech company, $700M upfront for rights to a bispecific antibody treatment code-named CN201. Several approved #celltherapies and bispecific drugs have already proven able to treat select blood #cancers. Research has suggested the same strategy can be used to treat #autoimmunediseases and CN201 has the potential to become a “novel, scalable option” for #autoimmune. Roche has two drugs in early testing, Zenas Biopharma will soon begin Phase 2 trials in #lupus and #multiplesclerosis while Cullinan Therapeutics is on the verge of trials in lupus and #rheumatoidarthritis.

𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗹𝗮𝘀𝘁 𝘄𝗲𝗲𝗸 🇧🇪 Confo Therapeutics closes €60m Series B financing to advance GPCR-targeted drug development. Source: https://cl.gy/Pjwni 🇩🇰 Novo Nordisk's GLP-1 drug liraglutide slows cognitive decline in Alzheimer's, showing potential brain protective effects. Source: https://cl.gy/WHMIB 🇩🇰 Novo Nordisk's Ozempic could help diabetics curb cigarette use, study finds. Source: https://cl.gy/NGoKJ 🇪🇺🇯🇵 Eisai faces EU regulatory setback as panel advises against Leqembi approval or-alzheimers. Source: https://cl.gy/bpoQn 🇫🇷 Gourmey files first EU application for cell-based meat. Source: https://cl.gy/TaEUx 🇫🇷 🇯🇵 Sanofi drops Phase 2 dwarfism drug in rare disease pipeline clear-out. Source: https://cl.gy/jLqUQ 🇩🇪 🇺🇸 BioNTech and Regeneron's mRNA cancer vaccine combo shows efficacy in advanced melanoma Phase II trial. Source: https://cl.gy/fbMKq 🇩🇪 Boehringer pays $1.3B to acquire Nerio and its preclinical checkpoint inhibitors. Source: https://cl.gy/jxakp 🇩🇪 Boehringer buys Nerio Therapeutics for $1.3B to boost immuno-oncology pipeline. Source: https://cl.gy/lVRBe 🇩🇪 🇯🇵 Merck's Keytruda combo gets CHMP positive opinion in urothelial carcinoma. Source: https://cl.gy/njxuZ 🇬🇧 GSK inks $7.2B discovery deal with Flagship Pioneering. Source: https://cl.gy/MaRfB 🇬🇧 GSK partners with Flagship Pioneering in a $7B biobucks respiratory and immunology pact. Source: https://cl.gy/nAWZs 🇳🇱 Argenx reinvigorates clinical plans for Vyvgart after strong Q2 sales. Source: https://cl.gy/FKEWv 🇨🇭 Roche accelerates development of obesity assets from $2.7B Carmot acquisition. Source: https://cl.gy/bJAUk 🇨🇭 Roche halts Pompe gene therapy after evaluating competition. Source: https://cl.gy/gberM 🇨🇭 AC Immune bags FDA Fast Track designation for its Alzheimer's vaccine. Source: https://cl.gy/IhyRU  🇨🇭🇺🇸 Novartis and Dren Bio ink $3B deal for anti-myeloid bispecific antibodies. Source: https://cl.gy/urjID 🇨🇭 🇺🇸 Novartis announces partnership with Dren Bio, targeting new cancer treatments. Source: https://cl.gy/sXuMW Please like and any comments will be very well appreciated 👍